Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Stock Has Consensus Target Price of $197.50

Shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) have received an average recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $197.50.

A number of analysts have issued reports on the company. Cantor Fitzgerald began coverage on Sol-Gel Technologies in a report on Wednesday, October 14th. They issued an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sol-Gel Technologies in a research report on Tuesday, September 1st. Zacks Research upgraded Sol-Gel Technologies from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Sol-Gel Technologies in a research report on Monday, October 19th.

Insider Transactions at Sol-Gel Technologies

In other news, major shareholder Opaleye Management Inc. bought 1,493 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average cost of $65.94 per share, for a total transaction of $98,448.42. Following the purchase, the insider owned 540,000 shares of the company’s stock, valued at approximately $35,607,600. This trade represents a 0.28% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders bought a total of 53,430 shares of company stock worth $3,684,739 in the last 90 days. Corporate insiders own 66.51% of the company’s stock.

Institutional Trading of Sol-Gel Technologies

An institutional investor recently bought a new position in Sol-Gel Technologies stock. Affinity Asset Advisors LLC purchased a new position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 35,000 shares of the company’s stock, valued at approximately $2,773,000. Affinity Asset Advisors LLC owned approximately 1.25% of Sol-Gel Technologies at the end of the most recent quarter. Institutional investors and hedge funds own 26.18% of the company’s stock.

Sol-Gel Technologies Price Performance

NASDAQ SLGL opened at $68.35 on Monday. The stock has a market capitalization of $223.78 million, a PE ratio of -12.12 and a beta of 1.14. Sol-Gel Technologies has a 12-month low of $28.81 and a 12-month high of $97.97. The company has a 50 day moving average price of $69.04 and a two-hundred day moving average price of $73.91.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings results on Friday, August 21st. The company reported ($1.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.36) by $1.23. The company had revenue of $0.59 million during the quarter, compared to analysts’ expectations of $0.07 million. Sol-Gel Technologies had a negative return on equity of 44.05% and a negative net margin of 910.14%. As a group, equities analysts anticipate that Sol-Gel Technologies will post -5.37 EPS for the current year.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd. is a dermatology-focused specialty pharmaceutical company based in Israel. The company develops and commercializes topical prescription medicines for common skin conditions, using proprietary delivery technologies designed to improve the stability, tolerability, and effectiveness of active pharmaceutical ingredients.

Its marketed products include Epsolay, a topical benzoyl peroxide cream indicated for the treatment of inflammatory lesions associated with rosacea, and Twyneo, a fixed-dose topical combination of tretinoin and benzoyl peroxide for acne vulgaris.